A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat (RECOMM)

pharmaand

Status: Completed

Conditions: Multiple Myeloma

Treatments: Drug: Farydak

Study type: Observational

Funder types: Industry

Identifiers

NCT04150289

20192475

Details and patient eligibility

About

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Enrollment: 248 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Willing and able to provide written informed consent
• At least 18 years of age
• Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
• Initiating panobinostat within 60 days of enrollment
• ECOG performance status 0-1
• Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
• Willing and able to complete the PRO questionnaire

Exclusion criteria

• Diagnosed with any B-cell malignancy other than myeloma
• Estimated life expectancy <6 months
• Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)